Access recorded conference sections presented by local and international experts
Bayer breakfast symposium "Update on hypogonadism therapy"
Obesity, insulin resistance and type 2 diabetes are highly prevalent risk factors for the development of functional hypogonadotropic hypogonadism (commonly referred to as age-related testosterone deficiency).
Marija Pfeifer presents the results from a 2-year randomized placebo-controlled trial - “The impact of testosterone replacement therapy on glycemic control, vascular function, and components of the metabolic syndrome in obese hypogonadal men with type 2 diabetes” – which randomized 55 obese type 2 diabetic patients to treatment with testosterone undecanoate or placebo injections for 2 years.1
Results showed significant improvements in several metabolic parameters:
Reduced insulin resistance (HOMA-IR)
Reduced insulin, fasting blood glucose and HbA1c levels
Increased flow-mediated dilatation (a measure of endothelial function)
Reduced carotid intima media thickness (a measure of atherosclerosis)
Testosterone therapy also reduced the degree of liver fat content and improved the Aging Males' Symptoms scale (AMS) sexual score.
Prof. Dr. Med. Marija Pfeifer Medical Faculty University of Ljubljana, Slovenia
Groti K, Zuran I, Antonic B, Forsnaric L, Pfeifer M. The impact of testosterone replacement therapy on glycemic control, vascular function, and components of the metabolic syndrome in obese hypogonadal men with type 2 diabetes. The aging male : the official journal of the International Society for the Study of the Aging Male. 2018;21(3):158-169.Return to content